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Vitamin D deficiency has been associated with type 1 diabetes in observational studies, but
evidence from randomized controlled trials (RCTs) is lacking. The aim of this study was to
test whether genetically decreased vitamin D levels are causally associated with type 1 dia-
betes using Mendelian randomization (MR).
Methods and findings
For our two-sample MR study, we selected as instruments single nucleotide polymorphisms
(SNPs) that are strongly associated with 25-hydroxyvitamin D (25OHD) levels in a large vita-
min D genome-wide association study (GWAS) on 443,734 Europeans and obtained their
corresponding effect estimates on type 1 diabetes risk from a large meta-analysis of 12 type
1 diabetes GWAS studies (Ntot = 24,063, 9,358 cases, and 15,705 controls). In addition to
the main analysis using inverse variance weighted MR, we applied 3 additional methods to
control for pleiotropy (MR-Egger, weighted median, and mode-based estimate) and com-
pared the respective MR estimates. We also undertook sensitivity analyses excluding SNPs
with potential pleiotropic effects. We identified 69 lead independent common SNPs to be
genome-wide significant for 25OHD, explaining 3.1% of the variance in 25OHD levels. MR
analyses suggested that a 1 standard deviation (SD) decrease in standardized natural log-
transformed 25OHD (corresponding to a 29-nmol/l change in 25OHD levels in vitamin D–
insufficient individuals) was not associated with an increase in type 1 diabetes risk (inverse-
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variance weighted (IVW) MR odds ratio (OR) = 1.09, 95% CI: 0.86 to 1.40, p = 0.48). We
obtained similar results using the 3 pleiotropy robust MR methods and in sensitivity analyses
excluding SNPs associated with serum lipid levels, body composition, blood traits, and type
2 diabetes. Our findings indicate that decreased vitamin D levels did not have a substantial
impact on risk of type 1 diabetes in the populations studied. Study limitations include an
inability to exclude the existence of smaller associations and a lack of evidence from non-
European populations.
Conclusions
Our findings suggest that 25OHD levels are unlikely to have a large effect on risk of type 1
diabetes, but larger MR studies or RCTs are needed to investigate small effects.
Author summary
Why was this study done?
• Observational epidemiological studies have associated low vitamin D levels with risk of
type 1 diabetes; however, these studies are susceptible to confounding and reverse causa-
tion, and thus it remains unclear whether these associations are accurate.
• To our knowledge, there are no randomized controlled trials published to date on this
topic.
• If vitamin D insufficiency did cause type 1 diabetes, this would be of clinical relevance
for type 1 diabetes prevention in high-risk individuals, since vitamin D insufficiency is
common and safely correctable.
What did researchers do and find?
• We applied a Mendelian randomization study design to understand if vitamin D levels
are associated with a higher risk of type 1 diabetes. This approach offers an alternative
analytical technique able to reduce conventional patterns of confounding and reverse
causation and reestimate observations in a framework allowing causal inference.
• Our study did not find evidence in support of a large effect of vitamin D levels on type 1
diabetes. However, the findings do not exclude the possibility that there may be smaller
effects than we could not detect.
What do these findings mean?
• Our findings suggest that the previous epidemiological associations between vitamin D
and type 1 diabetes could be due to confounding factors, such as latitude and exposure
to sunlight.
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• Our results do not support increasing vitamin D levels as a strategy to decrease the risk
of type 1 diabetes.
Introduction
Type 1 diabetes is a relatively common autoimmune disease affecting the pancreatic beta cell.
Its incidence is increasing worldwide [1], and it inflicts substantial life-long morbidity, affect-
ing patients during childhood and throughout their adult life. Currently, there are no known
therapies that can be used in the prevention of type 1 diabetes, but evidence exists that low vita-
min D level may play a role in predisposition to this disease.
Animal studies [2–5] and observational studies [6–10] have shown that reduced levels of
serum 25 hydroxyvitamin D (25OHD) are associated with an increased risk of type 1 diabetes.
Additionally, it has been shown that vitamin D could prevent cytokine-induced apoptosis of
human pancreatic islets [11]. In an observational birth cohort of 10,366 children, vitamin D
supplementation was associated with a decreased risk of type 1 diabetes as compared to those
who did not receive supplementation (relative risk (RR): 0.12, 95% CI 0.03 to 0.51) [6]. In a
large prospective study on 8,676 children from the TEDDY cohort, the authors reported a
weak association between 25OHD levels and odds of type 1 diabetes (odds ratio (OR) = 0.93
for a 5-nmol/L difference; 95% CI 0.89, 0.97) [12]. The most recent observational evidence
comes from a nested case-control study in the TRIGR cohort, which showed a protective role
of higher 25OHD levels [13].
Conversely, a recent study on 1,316 children with diagnosed type 1 diabetes showed an
unexpected inverse association between vitamin D intake and fasting C-peptide, a marker of
residual insulin production from the pancreatic beta cell [7]. A small prospective study in 252
Finnish children showed no difference in 25OHD levels among these who progressed to type 1
diabetes compared to controls [14]. A larger observational study in children at risk for type 1
diabetes showed that neither increased 25OHD levels nor vitamin D supplementation were
associated with islet autoimmunity [15], while a separate study showed no difference in
25OHD levels of newly diagnosed children with type 1 diabetes compared to those of their
healthy siblings [16]. Another prospective study [17] demonstrated an association of low
25OHD with presence of pancreatic islet autoantibodies but not with progression to type 1 dia-
betes. It is important to note that prospective studies of the effect of 25OHD levels on type 1
diabetes starting before the occurrence of islet autoantibodies are less susceptible to reverse
causation compared to other study types in the field.
The link between vitamin D and type 1 diabetes may be mediated by the effects of vitamin
D on the immune system. There is evidence that the active form of vitamin D, 1,25-dihydroxy-
vitamin D, is an immune modulator, reducing activation of the immune system [18]. It has
been argued that vitamin D has also nonimmunologic effects on the pancreas and thus may
directly influence beta-cell function [19].
The reason the epidemiological associations have not led to changes in clinical care is
because the aforementioned observational studies can be hampered by confounding or reverse
causation. In this scenario, confounding could cause a spurious association if vitamin D and
type 1 diabetes are actually linked through an unobserved association with another disease
determinant, such as latitude or ethnicity. According to the “sunshine hypothesis” [20], the
increasing prevalence of this disease can be explained by the fact that less time is spent out-
doors and there is less exposure to ultraviolet radiation, leading to vitamin D deficiency. This
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hypothesis basically comes from the observation that countries closer to the equator have
lower rates of type 1 diabetes [21] and from the seasonal variations in its incidence, with most
cases being diagnosed in winter [22]. Also, patients affected by type 1 diabetes are more sensi-
tive to ultraviolet radiation and have less skin pigmentation than healthy controls [23], which
could suggest that reduced sun exposure might account for the low level of vitamin D in these
patients. Reverse causation can represent another limitation of the observational studies. For
instance, the onset of type 1 diabetes may lead individuals to remain indoors because of fear of
hypoglycemia with physical activity, which would decrease vitamin D levels due to reduced
sunlight exposure. Given these findings and in the absence of evidence from randomized con-
trolled trials (RCTs), strongly implicating vitamin D as a causal factor in etiology of type 1 dia-
betes in humans remains difficult.
However, support for a causal role for vitamin D in type 1 diabetes would have important
public health implications. The prevalence of this disease under the age of 14 years old is expected
to rise by 3% annually worldwide [24]. In addition, the prevalence of vitamin D insufficiency is
estimated to be 43% in the general population [25] and is also increasing [26]. There is a signifi-
cant economic burden and long-term care costs associated with type 1 diabetes [27]. In contrast,
an annual supply of 1,000 IU vitamin D supplements satisfying the Institute of Medicine’s intake
guidelines for sufficiency [28] costs approximately $30 to $40. Therefore, ensuring vitamin D suf-
ficiency among individuals at high risk for type 1 diabetes may be explored as a cost-effective
approach to reduce risk, if clinical trial evidence supports a role for vitamin D administration in
the prevention of this disease. Despite this, the considerable controversy in the available epidemi-
ological data has prevented the conduct of large-scale RCTs, also because such trials would be
expensive and reliant upon funding of the public purse, since vitamin D cannot be patented.
Therefore, it is necessary to better understand the causal relationship between vitamin D and
type 1 diabetes in humans, in order to provide evidence to support or not a costly RCT.
Mendelian randomization (MR) is a method in genetic epidemiology which uses genetic
variants reliably associated with exposures of interest to estimate causal associations between a
given biomarker, such as vitamin D, and disease. These studies have orthogonal assumptions
to conventional techniques and are arguably less prone to reverse causation since disease states
usually do not change the germline DNA sequences [29]. Most importantly, MR can limit con-
founding, since genotypes are randomly assorted at meiosis [30]. In this regard, the MR frame-
work can be compared to that of an RCT because the random assortment of genetic variants
replicates the random allocation of study participants to different therapeutic arms. Lastly,
since genetic variants remain stable over a lifetime, MR studies provide insights from a lifetime
of genetically altered biomarker levels, which, in this case, is lowered 25OHD levels. Therefore,
we elected to perform an MR study using single nucleotide polymorphisms (SNPs) from the
largest genome-wide association study (GWAS) for vitamin D to date on 443,734 Europeans
[31], and their effects on type 1 diabetes from a recent large meta-analysis of GWAS on 9,358
cases and 15,705 controls [32].
Methods
The present study did not follow a prespecified analysis plan or protocol. Ethics approval was
not required for this study. We provide a completed STrengthening the Reporting of OBserva-
tional studies in Epidemiology (STROBE) checklist for the study (see S1 STROBE Checklist).
Genetic variants associated with vitamin D
To assess whether genetically lowered vitamin D levels are associated with increased odds of
type 1 diabetes, we identified, among the conditionally independent SNPs of a large 25OHD
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GWAS meta-analysis (n = 443,734) [31], the lead common independent SNPs associated with
25OHD. To satisfy the first MR assumption, which requires that the instrument (SNP)
robustly associates with the exposure (25OHD level), we chose as instruments SNPs which
were associated with 25OHD levels at a level of genome-wide significance (p< 6.6 × 10−9). We
selected only common SNPs among the conditionally independent SNPs, to ensure that our
instruments are truly in linkage equilibrium, since the r2 as metric of linkage disequilibrium
(LD) is less accurate for rare variants [33]. Also, rare variants with minor allele frequency
(MAF) <0.5% were generally absent in the type 1 diabetes GWAS. We extracted estimates of
the effects of these 25OHD-associated variants on type 1 diabetes from a large GWAS meta-
analysis of 12 European studies, totaling 9,358 cases and 15,705 controls [32]. Details on the
demographics of the cohorts participating in the 25OHD and type 1 diabetes GWAS can be
found in the respective publications [31,32]. We also estimated the total variance explained in
25OHD by our genetic instruments. The variance explained for a given SNP was calculated
using the formula: variance explained = 2β 2 ƒ (1 –ƒ), where β and ƒ denote the effect of the
SNP on 25OHD level and the MAF, respectively.
For 25OHD-related variants not directly present in the type 1 diabetes GWAS, we selected
proxy SNPs in LD (r2 > 0.7) using the LDproxy function in LD link (https://ldlink.nci.nih.
gov) and all EUR populations from 1,000 genomes phase 3.
Mendelian randomization analyses
We performed a main analysis using an inverse-variance weighted (IVW) two-sample MR to
estimate the effect of a 1 standard deviation (SD) increase in standardized natural log-trans-
formed 25OHD on type 1 diabetes susceptibility, using previously described methods [34].
Specifically, the effect of each variant on risk of type 1 diabetes was weighted by its effect on
25OHD using the Wald ratio method. These individual MR estimates were then combined in
a random effect inverse-variance meta-analysis. To help the interpretation of our MR results,
we also expressed our MR estimates as the effect of a given nmol/l change in 25OHD levels
(corresponding to 1 SD in standardized natural log-transformed 25OHD) in vitamin D–defi-
cient, vitamin D–insufficient, and vitamin D–sufficient individuals, defined as individuals hav-
ing 25OHD levels at the clinically relevant thresholds of 25, 50, and 70 nmol/l, respectively.
The second MR assumption requires that the instruments (SNPs) are not associated with
phenotypes that could confound the association between the exposure and the outcome. As a
sensitivity analysis, MR estimates excluding variants associated with potential confounders
were calculated. To do so, we queried in the PhenoScanner database each 25OHD-related SNP
used as instrument, in order to identify genetic variants associated with GWAS traits that are
potential confounders or could introduce horizontal pleiotropy in the exposure-outcome asso-
ciation (associating variants). We considered positive associations whenever the GWAS p-
value of the variant for a trait was below the nominal p-value Bonferroni-corrected for the
number of genetic variants (p< 0.05/69 = 0.001). Associations with specific traits appearing
more than once per SNP in our Phenoscanner search (meaning that they were present in more
than one GWAS) were counted as single entries. Certain traits clustered into larger trait cate-
gories; therefore, we grouped these into 14 trait categories (S2 Table). We then counted the
number of SNP-trait associations and looked for enrichments of each of the 25OHD SNPs in
traits clustering into the 14 categories. While we did not detect associations of our MR SNPs
with traits considered as confounders in the association between vitamin D and type 1 diabetes
(and therefore eliminated the risk of horizontal pleiotropy), we selected the top 3 trait catego-
ries (S1 and S2 Tables), defined as the categories that accumulated the most SNP-trait associa-
tions, and performed sensitivity analyses excluding SNPs mapping in each of these 3 categories
PLOS MEDICINE Vitamin D and type 1 diabetes: a Mendelian randomization study
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003536 February 25, 2021 5 / 16
respectively. We additionally performed a sensitivity analysis excluding SNPs associated with
type 2 diabetes and related traits. The rationale for performing sensitivity analyses by omitting
SNPs associated with these traits is that the latter might explain how the SNPs act upon
25OHD levels or explain downstream effects (vertical pleiotropy).
The third MR assumption is that the genetic variants must not be associated with the out-
come through pathways other than the exposure of interest (referred to as exclusion restriction
assumption) [34]. In the context of MR, horizontal pleiotropy refers to a scenario in which this
assumption is breached. To test this assumption, we applied different approaches which
account for potential pleiotropic effects. First, we tested for heterogeneity of the SNPs used as
instruments and generated MR estimates omitting SNPs appearing as outliers [35]. We then
applied MR-Egger regression to account for potentially unmeasured pleiotropy [36]. This
method consists of a weighted linear regression of the SNP-type 1 diabetes susceptibility on
the SNP-25OHD associations. This allows the estimation of an intercept as a measure of the
average pleiotropic effect and produces a slope coefficient as a robust to pleiotropy MR esti-
mate. MR-Egger allows a weakening of the exclusion restriction assumption and requires the
association of each variant with 25OHD not be correlated with its pleiotropic effect (known as
the InSIDE assumption). Additionally, we performed a weighted median analysis [37], which
weights individual MR estimates by their precision. This approach relies on the fact that esti-
mates from SNPs without pleiotropic effects are more likely to converge toward the median,
while we could expect that pleiotropy will introduce heterogeneity and result in relative outli-
ers. This method provides reliable results when less than 50% of the total weight is coming
from variants with pleiotropic effects. Finally, we used a similar approach to the previous, but
that relies on a mode-based estimate rather than the median, allowing for even the majority of
SNPs to be pleiotropic [38]. Lastly, to further ensure that our estimates were not influenced by
pleiotropy, we repeated the MR analysis using only 6 genetic variants for 25OHD levels identi-
fied in a previous GWAS and also undertook a separate analysis using 4 among these 6 SNPs,
which lie in or next to the DHCR7, CYP2R1, GC, CYP24A1 genes which directly regulate vita-
min D synthesis or degradation [39]. By undertaking this variety of sensitivity analyses, and
comparing results using these approaches, each one with different underlying assumptions, we
ensured that it is unlikely that our findings are biased by of pleiotropy.
We therefore used the MendelianRandomization R package [40], and its default parame-
ters, to compute the 4 different MR estimates [IVW, weighted median, random-effects
MR-Egger, and mode-based estimate (MBE)] for the main analysis, including all SNPs, and in
the sensitivity analyses omitting SNPs associated with confounders, and proxy SNPs. Notably,
the “random” model was selected in the MR Egger and IVW methods, given the presence of
heterogeneity in our instruments. The “penalized” parameter also penalized variants with het-
erogeneous causal estimates. We used the same package to generate scatter plots to compare
the MR estimates using different methods. As an additional control for pleiotropy, we applied
the global test, outlier test, and distortion test using the MR pleiotropy residual sum and outlier
(MR-PRESSO) R package [35]. Specifically, the global test detects horizontal pleiotropy among
the MR instruments; the outlier test corrects for horizontal pleiotropy via outlier removal; the
distortion test identifies significant distortion in the causal estimates before and after outlier
removal.
The type 1 diabetes GWAS was restricted to individuals of European descent, similar to the
25OHD GWAS, in order to limit bias from population stratification. Finally, we undertook
power calculations using the method published by Brion and colleagues [41] to test whether
our study was adequately powered to detect clinically relevant changes in type 1 diabetes risk.
To do this, we set the alpha level to 0.05 and used the estimate of the variance explained by the
25OHD-related SNPs produced by the aforementioned formula.
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Results
SNP selection and genetic effect sizes on 25OHD
We used 69 lead common independent SNPs (S1 Table), explaining 3.1% of the variance in
25OHD levels, as instruments in our MR studies. Eight out of the 69 SNPs were absent in the
type 1 diabetes GWAS and were replaced by proxies in high LD (r2 > 0.7) (Table 1). Our Phe-
noScanner search did not reveal any associations, at a Bonferroni-corrected threshold, with
any known potentially pleiotropic pathways influencing these 2 outcomes. However, we
observed an enrichment in SNPs associated with certain trait categories, in particular blood
cell counts, body composition, and serum lipid traits (S1 Table). Specifically, among 1,641
SNP-trait associations with 494 individual traits found by our PhenoScanner search, we
observed 246 associations with blood cell counts, 250 associations with body composition
traits, and 213 associations with serum lipids. A full description of the SNP-trait associations is
provided in S2 Table. We then undertook sensitivity analyses excluding SNPs clustering in
each of these 3 trait categories and also excluding SNPs associated with type 2 diabetes–related
traits.
The results of the MR analyses are shown in Figs 1–3 and Table 1. We did not find evi-
dence supporting a causal association between 25OHD levels and risk of type 1 diabetes (IVW
MR OR = 1.09, 95% CI: 0.86 to 1.40, p = 0.48 per 1 SD decrease in standardized log-trans-
formed 25OHD). Similar results were obtained using the other 3 MR methods. We estimated
that a 1 SD change in standardized natural-log transformed 25OHD levels corresponds to a
change in 25OHD levels of 40.9 nmol/l in vitamin D–sufficient individuals (defined as individ-
uals having 25OHD levels of 70 nmol/l), of 29.2 nmol/l in vitamin D–insufficient individuals
(defined as having 25OHD levels of 50 nmol/l), and of 14.6 nmol/l in vitamin D–deficient indi-
viduals (defined as having 25OHD levels of 25 nmol/l). Of note, a 29.2-nmol/l change in
25OHD levels is comparable to the 21.2 nmol/L mean increase in 25OHD levels conferred by
taking daily 400 IU of cholecalciferol, the amount of vitamin D most often found in vitamin D
supplements [42].
There was evidence of heterogeneity across the individual MR estimates derived from the
69 SNPs in the main MR analyses (IVW Q> 100, p-value� 0.002 in both MR studies). The
intercept estimated from the MR-Egger regression was centered around zero (−0.009, p-
value = 0.1) and did not provide strong evidence for unbalanced horizontal pleiotropy. How-
ever, using MR-PRESSO, we found evidence for pleiotropy (p-value global test 0.001). The MR
estimates for type 1 diabetes did not alter the inference of the results after removing 1 outlier
SNPs with increased evidence of pleiotropic effects (S3 Table). Moreover, we conducted sensi-
tivity analyses after removing subsequently 8 proxy SNPs, 35 SNPs associated with blood cell
counts, 23 SNPs associated with body composition, and 22 SNPs associated with lipid pheno-
types for both outcomes, and also 9 type 2 diabetes SNPs (S1 and S2 Tables). All sensitivity
analyses yielded results similar with those of the main analyses. The results of these sensitivity
analyses appear in Figs 1–3. Finally, using only the 6 SNPs for 25OHD identified in a previous
GWAS [39], we obtained similar estimates (IVW MR OR = 0.96, 95% CI: 0.58 to 1.58, p = 0.86
per 1 SD decrease in standardized log-transformed 25OHD) (S4 Table). When we limited our
MR instruments to only 4 among these 6 SNPs (which involve genes with direct role in vitamin
D synthesis and metabolism explaining 2.4% of the variance in 25OHD levels), the results
were similar (IVW MR OR = 0.92, 95% CI:0.53 to 1.62, p = 0.78).
Based on a sample size of 25,063 individuals and setting alpha to 0.05, and the variance
explained to 3.1%, our study had a power of 80% power to exclude effects on type 1 diabetes as
small as an OR of 1.23 per 1 SD change in 25OHD on the log scale and a power of 100% to
exclude effects as small as an OR of 1.4.
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Table 1. Results of the MR study testing causal association between low 25OHD and type 1 diabetes.
Full analysis with all SNPs (N = 69)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.093 0.855 1.396 0.478 heterogeneity: Q = 113.9;
p < 0.001
Weighted median 1.139 0.882 1.472 0.318
MR-Egger (random) 1.314 0.948 1.821 0.101 −0.009435201 0.099 heterogeneity Q = 109.5;
p < 0.001; I2 univariable
MR-Egger = 0.9931612
MBE (simple,1) 1.143 0.902 1.447 0.268
excluding proxy SNPs (N = 61)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.090 0.844 1.407 0.510 heterogeneity: Q = 101.6;
p < 0.001
Weighted median 1.139 0.875 1.483 0.334
MR-Egger (random) 1.261 0.902 1.764 0.175 −0.007952573 0.191 heterogeneity Q = 98.8
p < 0.001; I2 univariable
MR-Egger = 0.9938547
MBE (simple,1) 1.121 0.888 1.415 0.337
excluding lipids SNPs (N = 47)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.050 0.818 1.347 0.703 heterogeneity: Q = 70.0;
p = 0.00127
Weighted median 1.132 0.881 1.456 0.332
MR-Egger (random) 1.260 0.918 1.730 0.153 −0.01102054 0.077 heterogeneity Q = 65.5;
p = 0.0246; I2 univariable
MR-Egger = 0.9951814
MBE (simple,1) 1.109 0.880 1.398 0.381
excluding blood cell SNPs (N = 34)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.171 0.741 1.852 0.498 heterogeneity: Q = 72.2;
p < 0.001
Weighted median 1.577 0.948 2.623 0.079
MR-Egger (random) 1.738 0.861 3.508 0.123 −0.01539115 0.151 heterogeneity Q = 67.8;
p < 0.001; I2 univariable
MR-Egger = 0.9878622
MBE (simple,1) 1.212 0.785 1.871 0.386
excluding body composition SNPs (N = 46)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.111 0.882 1.400 0.372 heterogeneity: Q = 56.7;
p = 0.1124
Weighted median 1.161 0.885 1.522 0.281
MR-Egger (random) 1.418 1.066 1.884 0.016 −0.01466228 0.009 heterogeneity Q = 49.2;
p = 0.2737; I2 univariable
MR-Egger = 0.9950168
MBE (simple,1) 1.218 0.950 1.562 0.120
excluding diabetes SNPs (N = 60)
Analysis Odds ratio CI lower CI upper p-value Egger intercept Intercept p-value
Inverse variance weighted (random) 1.112 0.862 1.436 0.414 heterogeneity: Q = 101.7;
p < 0.001
Weighted median 1.149 0.882 1.497 0.304
MR-Egger (random) 1.354 0.971 1.888 0.074 −0.01072743 0.077 heterogeneity Q = 96.5;
p = 0.0011; I2 univariable
MR-Egger = 0.9939633
MBE (simple,1) 1.179 0.935 1.487 0.165
The OR are per 1 standard deviation decrease in standardized log-transformed 25OHD.
25OHD, 25-hydroxyvitamin D; CI, confidence interval; MBE, mode-based estimate; MR, Mendelian randomization; SNP, single nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1003536.t001
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Fig 1. Forest plot of the MR study investigating the effect of 25OHD on type 1 diabetes. Forest plot of the main study and of the
sensitivity analysis excluding proxy SNPs. 25OHD, 25-hydroxyvitamin D; MR, Mendelian randomization; SNP, single nucleotide
polymorphism.
https://doi.org/10.1371/journal.pmed.1003536.g001
Fig 2. Forest plot of the MR sensitivity analyses excluding SNPs with possible pleiotropic effects. The odds ratios
for type 1 diabetes are reported for a 1 standard deviation decrease in 25OHD on the log scale. 25OHD,
25-hydroxyvitamin D; CI, confidence intervals; MR, Mendelian randomization; OR, odds ratio; SNP, single nucleotide
polymorphism.
https://doi.org/10.1371/journal.pmed.1003536.g002
PLOS MEDICINE Vitamin D and type 1 diabetes: a Mendelian randomization study
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003536 February 25, 2021 9 / 16
Discussion
The results of this MR study do not support a causal association between a genetically deter-
mined change in 25OHD levels—comparable to the effect of a conventional dose of vitamin D
supplementation in a vitamin D–insufficient individual—and risk of type 1 diabetes. Our find-
ings confidently exclude large effects (OR>1.40), given the sufficient statistical power and the
consistency of the estimates using different MR methods and in the sensitivity analyses. How-
ever, the relatively large confidence intervals of our MR result suggests that small effects cannot
be excluded, and further evidence is needed to investigate such effects.
Our results are generally in contrast with observational evidence, largely from northern
European populations, supporting a role of low 25OHD in type 1 diabetes [12,13]. They are
consistent with those of 3 prospective studies [14,15,17], but, due to the nature of the MR anal-
ysis, are less prone to confounding and reverse causation. Our findings are also in agreement
with those of a recent observational study in individuals residing in a solar-rich environment
[9].
Fig 3. Scatter plot of the main MR study investigating the effect of 25OHD on type 1 diabetes. The x-axis represents the genetic association with 25OHD levels;
the y-axis represents the genetic association with risk of type 1 diabetes. Each line represents a different MR method. 25OHD, 25-hydroxyvitamin D; MR, Mendelian
randomization.
https://doi.org/10.1371/journal.pmed.1003536.g003
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No previous MR studies have been performed to investigate this research hypothesis.
Although associations between genetic variants influencing 25OHD levels and risk of type 1
diabetes have been studied in previous works by Cooper and colleagues [43] and Thorsen and
colleagues [44], the authors of these papers reported straightforward associations of these vari-
ants with disease status in cohorts of type 1 diabetes cases and controls. More recently, a phe-
nome-wide association study by Meng and colleagues [45] examined associations between a
polygenic risk score for 25OHD levels comprising 6 SNPs and 920 phenotypes in UK Biobank,
among which was type 1 diabetes. The authors found no evidence for positive association of
25OHD with type 1 diabetes. The 3 aforementioned studies do not fulfill the criteria of an MR
approach. Also, since these studies were published, our knowledge on vitamin D genetics was
substantially expanded with the publication of large vitamin D GWAS meta-analyses [31], pro-
viding more precise association tests and a new set of 25OHD SNPs explaining a larger portion
of the variance in 25OHD levels.
Our MR approach has several strengths. First, its design decreases potential confounding or
reverse causation which are present in observational studies. Eliminating reverse causation is
important since type 1 diabetes may be characterized by a preclinical phrase, which renders it
difficult to determine whether an exposure precedes the pathological changes to the pancreatic
beta cell. Our analysis also captures lifetime risk of type 1 diabetes due to genetically decreased
vitamin D, which again is important since a single vitamin D measurement is unlikely to be an
accurate predictor of a disease that manifests later in life. Lastly, by employing the two-sample
MR approach, we were able to test the effect of vitamin D in a large cohort of type 1 diabetes
patients (N = 9,358 type 1 diabetes cases and 15,705 controls). Such two-sample approaches
have statistical power comparable to an approach using individual-level data [46]; however,
few cohorts have accrued as many cases and controls for type 1 diabetes.
Our analysis also has limitations worth consideration. While we undertook multiple steps
to examine pleiotropy, residual bias is possible since the exact function of most of these SNPs
is unknown. Even in the case that pleiotropy was not properly accounted for by MR egger (if
the INSIDE assumption was violated by some of the SNPs used as instruments), the fact that
we obtained consistent results using another 2 pleiotropy robust MR methods and in sensitiv-
ity analyses excluding SNPs with pleiotropic effects is reassuring. Canalization is another
mechanism which may bias MR results toward the null. In this scenario, the effects of geneti-
cally reduced 25OHD levels on pathophysiology of type 1 diabetes may have been mitigated by
physiologic compensation [47], which, in this scenario, could lead to an increase conversion of
25OHD to its active form 1,25 dihydroxyvitamin D. In this regard, it might also be possible
that the immune effects of vitamin D on the beta cell are correlated to the levels of the active
form of vitamin D (1,25 dihydroxyvitamin D), which are weakly correlated with 25OHD lev-
els. Thus, although genetically lowered total 25OHD levels do not appear to be associated with
increased risk of type 1 diabetes, our study still leaves open the possibility that reduced lifelong
1,25 dihydroxyvitamin D is indeed associated with type 1 diabetes. However, changes in
25OHD levels are commonly measured to diagnose vitamin D insufficiency and monitor
response to vitamin D supplements, in contrast to 1,25 dihydroxyvitamin D levels, which are
unstable, have a short half-life, and are not routinely measured in clinical practice.
MR studies can assess the relationship between a biomarker and a disease only at the time
point in the life course where the genetic variant has been associated with the biomarker. This
may be important if the genetic determinants of 25OHD levels are different in adulthood
when compared to childhood, despite lack of evidence from the literature supporting this for
25OHD levels. In this regard, our study could not exclude effects of intrauterine exposure to
lower 25OHD levels in the risk of type 1 diabetes in the offspring which have been examined
in observational studies [48,49]. Despite the fact that the SNPs used as instruments in our MR
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were extracted from GWAS in Europeans, the populations of both GWAS were not homoge-
nous in terms of geographic location. It has been shown that there could be some gene-envi-
ronment interaction in the effect of SNPs in the vitamin D receptor gene on type 1 diabetes
risk [50]. Specifically, the effect of these SNPs on type 1 diabetes varies with levels of ultraviolet
irradiation, suggesting that the impact in vitamin D–deficient groups differs from that in non-
deficient population. This raises a possibility of gene-environment interaction for SNPs affect-
ing 25OHD levels and of nonlinear effects of these SNPs on risk of type 1 diabetes, but two-
sample MR studies can only assess linear associations. As such, they do not assess either the
effects on disease of having levels of a biomarker in the extremes of the normal distribution.
However, it is difficult to assess the impact of the above limitations in our MR study, given the
fact that prospective studies have reported a linear relationship between doses of vitamin D
supplementation and risk of type 1 diabetes [6]. Our MR results cannot be generalized to non-
Europeans and potentially to Europeans residing in different geographic areas than those of
the participants in the vitamin D and type 1 diabetes GWAS; and although we assured that
both exposure and outcome GWAS were restricted to participants of European ancestry, resid-
ual confounding from population stratification cannot be completely excluded in a two-sam-
ple MR setting, due to ethnic differences in the exposure and outcome GWAS populations
[51]. Finally, there is a possibility that our MR power calculation was overestimated due to
overfitting caused by the fact that the variance explained by the vitamin D SNPs was calculated
in the same population as the vitamin D GWAS. Unfortunately, we do not have access to an
independent cohort where the amount of variance explained by those SNPs could be
estimated.
In conclusion, our results identified no large impact of a genetically determined reduction
in 25OHD levels on type 1 diabetes risk. This provides critical insight into a complex disease
that remains poorly understood. Our findings imply that the observational associations
between 25OHD and risk of type 1 diabetes might be due to environmental confounders, such
as latitude, which is correlated with exposure to sun and skin pigmentation, but this needs to
be investigated in further studies. Since small effects cannot be excluded, our findings need to
be confirmed by large RCTs testing the effects of vitamin D supplements in type 1 diabetes, or
future MR evidence based on larger GWAS samples for 25OHD and type 1 diabetes risk.
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